Last week during the Annual Dutch Diabetes Research Meeting, Esther Phielix presented on behalf of Froukje Vanweert their work on the effects of lowering BCAA levels in patients with type 2 diabetes using sodium-phenylbutyrate (NaPB).
The key messages of this presentation were:
- 2-week NaPB treatment in patients with type 2 diabetes effectively reduced plasma BCAA levels
- The reduction of plasma BCAA levels in these patients was paralleled by a higher peripheral insulin sensitivity and glucose oxidation
- Our work strongly supports the notion that lowering plasma BCAA levels could be a potential strategy to promote insulin sensitivity in type 2 diabetes
